Compare AbbVie Inc (ABBV) vs Entegris Inc (ENTG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Entegris Inc — how do they compare? AbbVie Inc trades at $253.69 (market cap $449.91B), while Entegris Inc trades at $137.06 (market cap $20.57B). The key difference: AbbVie Inc is far larger — about 21.9× Entegris Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | ENTG | |
|---|---|---|
Market Cap | $449.91B | $20.57B |
Sector | Health | Technology |
52-Week High | $261.07 | $184.00 |
52-Week Low | $184.85 | $68.80 |
Enterprise Value | $513.38B | $23.89B |
Dividend Yield | 2.72% | 0.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
ENTG is trading at $135.08, down 7.9% today, with a bearish technical signal and neutral oscillators. The company reported strong Q1 2026 earnings of $0.86 per share, beating estimates, and maintains solid fundamentals with $3.2B revenue and 8.18% net income margin. Recent developments include a strategic cross-licensing agreement for EUV lithography and appointment of a new CFO.
Wall Street maintains a bullish outlook with 65% buy ratings and $178.40 consensus price target, representing 32% upside potential. Key risks include premium valuation (P/E 83.91), semiconductor cycle sensitivity, and execution challenges. The stock offers growth exposure to AI-driven semiconductor demand but requires careful monitoring of quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
